In a recent large multicenter retrospective cohort comparing the recurrence rate between 304 patients receiving adjuvant DAA therapy and 489 patients untreated after curative HCC treatment, patients in the DAA-treated arm had an HCC recurrence rate comparable to untreated patients (HR 0.90, 95% CI 0.70–1.16) over a median follow-up duration of 10.4 months, after adjustment for study site, age, sex, Child–Pugh score, AFP level, tumor burden, and HCC treatment modality [139]. This evidence concerns the gene AFP and hepatocellular carcinoma.